References
- Huggins C, Bergenstal DM. Inhibition of Human Mammary and Prostatic Cancers by Adrenalectomy. Cancer Res 1952; 12:134 - 141
- Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, et al. American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer. J Clin Oncol: JCO 2009; 26:3756
- Pal S, Pegram M. HER2 targeted therapy in breast cancer…beyond Herceptin. Rev Endocr Metab Disord 2007; 8:269 - 277
- Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666 - 2676
- O'Shaughnessy JA, Brufsky AM. RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer. Clin Breast Cancer 2008; 8:370 - 373
- Young E, Miele L, Tucker KB, et al. SU11248: A Selective Tyrosine Kinases Inhibitor Suppresses Breast Tumor Angiogenesis and Growth via Targeting both Tumor Vasculature and Breast Cancer Cells. Cancer Biol Ther 2010; 10:703 - 711
- Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells. Cancer Res 2009; 69:2506 - 2513
- Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, et al. Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients. Clin Can Res 2008; 14:6674 - 6682
- Chow LQM, Eckhardt SG. Sunitinib: From Rational Design to Clinical Efficacy. J Clin Oncol 2007; 25:884 - 896
- Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368:1329 - 1338
- Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al. Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor. J Clin Oncol 2008; 26:5352 - 5359
- Yang F, Jove V, Xin H, Hedvat M, Van Meter TE, Yu H. Sunitinib Induces Apoptosis and Growth Arrest of Medulloblastoma Tumor Cells by Inhibiting STAT3 and AKT Signaling Pathways. Mol Cancer Res 2010; 8:35 - 45
- Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, et al. Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. J Clin Oncol 2008; 26:1810 - 1816
- Barrios C, Liu MC, Lee S, Vanlemmens L, Ferrero JM, Tabei T, et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010; 121:121 - 131
- Mayer EL, Dhakil S, Patel T, Sundaram S, Fabian C, Kozloff M, et al. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol 2010; In press